Oryzon A joint investigation, Laboratorios Reig-Jofre and the Hospital de la Vall d'Hebron has allowed the development of a method for identifying biomarkers that enable early diagnosis of cancer of the uterus (endometrium). endometrial carcinoma is the most common cancer of female genital tract, representing 6% of all malignancies in women. It is the second most common cancer in women in Spain, after breast cancer and the fourth in incidence in the United States. In the past 30 years has been an increase in the diagnosis and also in the number of deaths attributable to this type of cancer, from 4000 deaths in 1990 in USA at a rough estimate of 7470 in 2008. Endometrial carcinoma occurs in women both in the breeding season and during the postmenopause. The highest incidence occurs from aa 50, although 5% are diagnosed before 40 years of age.
A draft business-academia joint research over three years, a team of scientists and business Oryzon-Reig Jofre in close collaboration with the Department and directed by Miguel Jaume Reventós Abal Research Unit Biomedical Research Institute, Hospital Universitario de la Vall de Hebron in Barcelona together with Antonio Gil of Service Gynaecology of the hospital run by Jordi Xercavins, has analyzed over 100 samples of patients endometrial cancer and patients with other illnesses or deaths healthy. DNAchip Using genomic analysis have been identified and subsequently verified by quantitative PCR technology, there are various combinations of markers able to identify with a sensitivity and specificity of nearly 100% of patients with cancer, from a uterine aspirate. Given the specificity of the primary symptom of endometrial cancer, abnormal uterine bleeding, it is important to determine the usefulness of biomarkers for the differential diagnosis of endometrial pathologies. For perimenopausal women is more difficult to suspect endometrial cancer because it is a time where there are many irregularities in the menstrual cycle. It is therefore essential to develop tools that allow a differential diagnosis for this patient group. This new system will reduce hysteroscopy and expedite cases of patients who require a rapid clinical and analyzing suspected in women with perimenopausal phase in the proliferative period of the cycle.
The results of this research have been already patented and have been submitted for publication in an international medical journal. The results are so promising that is expected to begin a multicenter clinical trial in the coming months. -Reig Jofre Oryzon and have collaborated on this project through a joint venture formed in 2006 GEADIC Biotec IEA, which has invested in this program more than 1 million euros and has been co-financed by the Government of Catalunya through ACC10 - ICW in Nuclis program for Innovation in 2007.
Research in this project has enabled the two companies identify a series of discoveries beyond their own markers, from which are opening new lines of future research, in which the partners maintain their commitment to investment. Source: Noticiasmedicas.es
